Annals of Oncology

News:

Wisdom word
Ann Oncol 12: 1183.
[PDF] [Request Permissions]

Are drug companies manipulating publications?
Ann Oncol 12: 1183.
[PDF] [Request Permissions]

How the fascination of cannabis misleads journalists
Ann Oncol 12: 1183.
[PDF] [Request Permissions]

Patients become anxious and medical care team is overwhelmed: Anxiety about tamoxifen once again
Ann Oncol 12: 1183-1184.
[PDF] [Request Permissions]

Annals is going well
Ann Oncol 12: 1184.
[PDF] [Request Permissions]

Americans may finally be reimbursed by Medicare for oral chemotherapy
Ann Oncol 12: 1184.
[PDF] [Request Permissions]

If this was our only anxiety about our adolescent kids?
Ann Oncol 12: 1184.
[PDF] [Request Permissions]

And which will be the next drug to go out of the market?
Ann Oncol 12: 1185.
[PDF] [Request Permissions]

Difficult times at Johns Hopkins
Ann Oncol 12: 1185.
[PDF] [Request Permissions]

There are unsafe places, but may be there is more to it than that...
Ann Oncol 12: 1185.
[PDF] [Request Permissions]

Undertreating cancer pain is a crime
Ann Oncol 12: 1185.
[PDF] [Request Permissions]

Perhaps not everyone knows that...
Ann Oncol 12: 1185-1187.
[PDF] [Request Permissions]

Book reviews:

C. Bouchardy

Book review
Ann Oncol 12: 1188.
[PDF] [Request Permissions]

C. S. McArdle

Book review
Ann Oncol 12: 1194.
[PDF] [Request Permissions]

Editorials:

J. Austoker

The potential and pitfalls for developing guidelines in oncology
Ann Oncol 12: 1189-1190.
[PDF] [Request Permissions]

C. B Steer, G. M Marx, and P G. Harper

Is there quality in clinical benefit?
Ann Oncol 12: 1191-1193.
[PDF] [Request Permissions]

Review:

M.J. Piccart, H. Lamb, and J. B. Vermorken

Current and future potential roles of the platinum drugs in the treatment of ovarian cancer
Ann Oncol 12: 1195-1203.
[Abstract] [PDF] [Request Permissions]

Special articles:

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of ovarian cancer
Ann Oncol 12: 1205-1207.
[PDF] [Request Permissions]

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin's lymphoma
Ann Oncol 12: 1209-1210.
[PDF] [Request Permissions]

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of relapsed large cell non-Hodgkin's lymphoma
Ann Oncol 12: 1211-1212.
[PDF] [Request Permissions]

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Hodgkin's disease
Ann Oncol 12: 1213-1214.
[PDF] [Request Permissions]

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of mixed or non-seminomatous germ cell tumours (NSGCT)
Ann Oncol 12: 1215-1216.
[PDF] [Request Permissions]

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of testicular seminoma
Ann Oncol 12: 1217-1218.
[PDF] [Request Permissions]

ESMO Recommendations for the application of haematopoietic growth factors (hGFs)
Ann Oncol 12: 1219-1220.
[PDF] [Request Permissions]

Original articles:

J. F. Vansteenkiste, J. E. Vandebroek, K. L. Nackaerts, P. Weynants, Y. J. Valcke, D. A. Verresen, R. C. Devogelaere, S. A. Marien, Y. P. Humblet, N. L. Dams, and The Leuven Lung Cancer Group

Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine
Ann Oncol 12: 1221-1230.
[Abstract] [PDF] [Request Permissions]

D.V. Skarlos, E. Samantas, E. Briassoulis, E. Panoussaki, N. Pavlidis, H. P. Kalofonos, D. Kardamakis, E. Tsiakopoulos, P. Kosmidis, D. Tsavdaridis, J. Tzitzikas, P. Tsekeris, G. Kouvatseas, N. Zamboglou, and G. Fountzilas

Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: A randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG)
Ann Oncol 12: 1231-1238.
[Abstract] [PDF] [Request Permissions]

Y. Soini, K. Järvinen, R. Kaarteenaho-Wiik, and V. Kinnula

The expression of P-glycoprotein and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) in human malignant mesothelioma
Ann Oncol 12: 1239-1245.
[Abstract] [PDF] [Request Permissions]

J. A. O'Shaughnessy, J. Blum, V. Moiseyenko, S. E. Jones, D. Miles, D. Bell, R. Rosso, L. Mauriac, B. Osterwalder, H.-U. Burger, and S. Laws

Randomized, open-label, phase II trial of oral capecitabine (Xeloda^®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
Ann Oncol 12: 1247-1254.
[Abstract] [PDF] [Request Permissions]

T. Skovsgaard, N. G. P. Davidson, M. J. Piccart, D. J. Richel, J. Bonneterre, D.T. Cirkel, C. M. Barton, and S. Knight

A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer
Ann Oncol 12: 1255-1257.
[Abstract] [PDF] [Request Permissions]

L. R. Laufman, C. H. Spiridonidis, J. Pritchard, R. Roach, J. Zangmeister, N. Larrimer, T. Moore, M. Segal, J. Jones, T. Patel, L. Gutterman, L. Carman, D. Colborn, and J. P. Kuebler

Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: A phase II trial
Ann Oncol 12: 1259-1264.
[Abstract] [PDF] [Request Permissions]

L. Zelek, S. Barthier, M. Riofrio, D. Sevin, K. Fizazi, and M. Spielmann

Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes
Ann Oncol 12: 1265-1268.
[Abstract] [PDF] [Request Permissions]

H. Ulrich-Pur, G.V. Kornek, W. Fiebiger, C. Gedlicka, M. Raderer, A. Lenauer, D. Depisch, F. Lang, J. Pidlich, and W. Scheithauer

Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy
Ann Oncol 12: 1269-1272.
[Abstract] [PDF] [Request Permissions]

T. M. Beer, W. C. Pierce, B. A. Lowe, and W. D. Henner

Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer
Ann Oncol 12: 1273-1279.
[Abstract] [PDF] [Request Permissions]

W. J. Köstler, T. Brodowicz, Y. Attems, M. Hejna, S. Tomek, G. Amann, W. C. C. Fiebiger, Ch. Wiltschke, M. Krainer, and Ch. C. Zielinski

Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: Results of a phase II trial
Ann Oncol 12: 1281-1288.
[Abstract] [PDF] [Request Permissions]

C. J. A. Punt, P. Fumoleau, B. van de Walle, M. N. Faber, M. Ravic, and M. Campone

Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-Early Clinical Studies Group (ECSG)
Ann Oncol 12: 1289-1293.
[Abstract] [PDF] [Request Permissions]

P. F. H. J. Quaedvlieg, O. Visser, C. B. H. W. Lamers, M. L. G. Janssen-Heijen, and B. G. Taal

Epidemiology and survival in patients with carcinoid disease in the Netherlands: An epidemiological study with 2391 patients
Ann Oncol 12: 1295-1300.
[Abstract] [PDF] [Request Permissions]

A. Di Paolo, R. Danesi, A. Falcone, L. Cionini, F. Vannozzi, G. Masi, G. Allegrini, E. Mini, G. Bocci, P. F. Conte, and M. Del Tacca

Relationship between 5-fluorouracil disposition, toxicity and dihydropy rimidine dehydrogenase activity in cancer patients
Ann Oncol 12: 1301-1306.
[Abstract] [PDF] [Request Permissions]

U. Rueffer, K. Breuer, A. Josting, B. Lathan, M. Sieber, O. Manzke, F.-J. Grotenhermen, H. Tesch, H. Bredenfeld, P. Koch, H. Nisters-Backes, J. Wolf, A. Engert, and V. Diehl

Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment
Ann Oncol 12: 1307-1311.
[Abstract] [PDF] [Request Permissions]

J.-L. Lagrange, A. Ramaioli, Ch. Theodore, M.-J. Terrier-Lacombe, V. Beckendorf, P. Biron, Ch. Chevreau, P. Chinet-Charrot, J. Dumont, A. Delobel-Deroide, J. D'Anjou, C. Chassagne, R.-M. Parache, J.-M. Karsenty, J. Merrier, J.-P. Droz, and RTG and the GETUG (FNCLCC)

Non-Hodgkin's lymphoma of the testis: A retrospective study of 84 patients treated in the French anticancer centres
Ann Oncol 12: 1313-1319.
[Abstract] [PDF] [Request Permissions]

Clinical cases:

A. Madroszyk, J. Egreteau, L. Martin, P. E. Queneau, J. F. Bosset, and Y. Merrouche

Small-cell carcinoma of the esophagus: Report of three cases and review of the literature with emphasis on therapy
Ann Oncol 12: 1321-1325.
[Abstract] [PDF] [Request Permissions]

M. J. J. Edwards, R. Walker, S. Vinnicombe, C. Barlow, P. MacCallum, and J. M. Foran

Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma
Ann Oncol 12: 1327-1329.
[Abstract] [PDF] [Request Permissions]

Letters to the editor:

F. Di Costanzo, S Gasperoni, A Falcone, L Dogliotti, L. Frassinetti, P. Bruzzi, and R Rosso

Repetita iuvant — INTACC (Intergruppo Italiano Terapia Adiuvante Carcinoma del Colon)
Ann Oncol 12: 1331.
[PDF] [Request Permissions]

J Wils on behalf of R Labianca and P O'Dwyer

Repetita iuvant — INTACC (Intergruppo Italiano Terapia Adiuvante Carcinoma del Colon)
Ann Oncol 12: 1331.
[PDF] [Request Permissions]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.